Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

doi:10.1126/science.abc7520

GSTDTAP > 气候变化

DOI	10.1126/science.abc7520
	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
	Thomas F. Rogers; Fangzhu Zhao; Deli Huang; Nathan Beutler; Alison Burns; Wan-ting He; Oliver Limbo; Chloe Smith; Ge Song; Jordan Woehl; Linlin Yang; Robert K. Abbott; Sean Callaghan; Elijah Garcia; Jonathan Hurtado; Mara Parren; Linghang Peng; Sydney Ramirez; James Ricketts; Michael J. Ricciardi; Stephen A. Rawlings; Nicholas C. Wu; Meng Yuan; Davey M. Smith; David Nemazee; John R. Teijaro; James E. Voss; Ian A. Wilson; Raiees Andrabi; Bryan Briney; Elise Landais; Devin Sok; Joseph G. Jardine; Dennis R. Burton
	2020-08-21
发表期刊	Science
出版年	2020
英文摘要	Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al. used a high-throughput pipeline to isolate and characterize monoclonal antibodies from convalescent donors. Antibodies were selected for binding to the viral spike protein, which facilitates entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. Most isolated antibodies bound to regions of the spike outside of the receptor binding domain (RBD); however, a larger proportion of the RBD-binding antibodies were neutralizing, with the most potent binding at a site that overlaps the ACE2 binding site. Two of the neutralizing antibodies were tested in Syrian hamsters and provided protection against SARS-CoV-2 infection. Science , this issue p. [956][1] Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–recovered participants, developed neutralization assays to investigate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen more than 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. As indicated by maintained weight and low lung viral titers in treated animals, the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs also define protective epitopes to guide vaccine design. [1]: /lookup/doi/10.1126/science.abc7520
领域	气候变化 ; 资源环境
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/291215
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Thomas F. Rogers,Fangzhu Zhao,Deli Huang,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model[J]. Science,2020.
APA	Thomas F. Rogers.,Fangzhu Zhao.,Deli Huang.,Nathan Beutler.,Alison Burns.,...&Dennis R. Burton.(2020).Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.Science.
MLA	Thomas F. Rogers,et al."Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model".Science (2020).